Longevity Economy

https://www.perplexity.ai/search/e60e1216-8ec9-46d7-b418-b591ffbb56d1
A compelling “Why now” case for a Longevity Fund can be grounded in demographic inevitability, accelerating deep-tech breakthroughs, and a rapidly scaling capital and economic landscape that now runs into the trillions of dollars.who+2​

Global aging and longevity demand

The World Health Organization estimates that the global population aged 60+ will grow from 1 billion in 2020 to 1.4 billion in 2030 and 2.1 billion by 2050, meaning roughly one in six people on earth will be over 60. UN and independent demographic analyses project that older cohorts (65+) will nearly double over the next three decades, pushing the share of older adults toward 16–22% of the global population and creating sustained demand for healthspan and longevity innovation. These shifts are structurally reshaping labor markets, social insurance systems, and healthcare, forcing both governments and private markets to seek scalable solutions that compress morbidity and extend productive years.who+5​

Breakthroughs in CRISPR, senolytics, and AI

Genome editing platforms such as CRISPR have moved from proof-of-concept to approved therapies, with multiple CRISPR-based treatments for severe genetic diseases now authorized or in late-stage trials, validating the modality and derisking the core toolchain for age-related indications. In parallel, senolytic and broader “senotherapeutic” strategies targeting senescent cells have advanced into human studies, and companies like Rubedo Life Sciences and Loyal have attracted sizable rounds to develop senolytics and longevity therapeutics for both humans and companion animals, signaling investor belief that these mechanisms can translate into commercial products. AI-driven drug discovery and “longevity discovery platforms” are now a leading financing category, with platform technologies alone attracting more than $2–2.6 billion in 2024, as investors back AI systems that can systematically discover, optimize, and de-risk pipelines for aging biology at scale.prnewswire+2​

Capital flows into longevity startups

Dedicated longevity investment has recently inflected upward, suggesting the sector is transitioning from speculative thesis to institutional theme. Longevity.Technology’s 2024 Annual Longevity Investment Report shows total financing in longevity companies reaching approximately $8.49 billion across 300+ deals in 2024, more than doubling the prior year’s levels and representing about a 220% increase despite fewer total deals. Later-stage venture capital dominated with around $2.7 billion in 2024, complemented by nearly $2.0 billion from public follow-on offerings and over $1.5 billion from private equity growth capital, indicating that capital is not only starting more companies but also scaling winners.longevity+3​

The multi‑trillion‑dollar longevity economy

The “longevity economy” — economic activity driven by older adults — is already measured in the trillions and growing. AARP and Oxford Economics estimated that Americans aged 50+ generated about $7.1–7.6 trillion in annual economic activity in the mid‑2010s alone, including trillions in GDP, wages, and tax revenues, and projected this to exceed $13.5 trillion by 2032 in real terms. Broader analyses now value the global longevity and aging-related sector in the low-to-mid tens of trillions (for example, estimates in the tens of trillions by 2030), underscoring that capturing even a modest share of products and services that extend healthy life, independence, and productivity for older adults can support multi‑billion‑dollar venture outcomes.press.aarp+4​
  1. https://www.who.int/news-room/fact-sheets/detail/ageing-and-health
  2. https://www.prnewswire.com/news-releases/longevity-investment-more-than-doubled-to-8-5bn-in-2024--302453871.html
  3. https://press.aarp.org/2016-09-20-AARP-Announces-Longevity-Economy-Accounts-for-7-6-Trillion-in-Economic-Activity-Up-From-7-1-Trillion-in-2013
  4. https://www.who.int/health-topics/ageing
  5. https://www.un.org/development/desa/en/news/population/our-world-is-growing-older.html
  6. https://lausanne.org/report/demographics/global-aging-population
  7. https://ourworldindata.org/data-insights/by-2060-the-number-of-people-aged-65-and-older-will-be-more-than-four-times-what-it-was-in-2000
  8. https://www.mckinsey.com/mgi/our-research/dependency-and-depopulation-confronting-the-consequences-of-a-new-demographic-reality
  9. https://longevity.technology/investment/report/annual-longevity-investment-report-2024/
  10. https://www.longevityinvestors.ch/post/the-global-longevity-investment-landscape-leading-investors-by-deal-count
  11. https://www.ainvest.com/news/longevity-tech-revolution-billionaire-driven-innovation-610-billion-opportunity-2509/
  12. https://www.weforum.org/stories/2024/02/longevity-economy-principles-ageing-population/
  13. https://www.house.mi.gov/Document/?DocumentId=43427&DocumentType=CommitteeTestimony
  14. https://www.tomorrow.bio/post/the-7-trillion-longevity-economy-why-defeating-aging-will-be-the-greatest-economic-value-creation-event-in-history-2023-09-5160718834-longevity
  15. https://theweek.com/business/longevity-economy-booming-live-longer
  16. https://www.un.org/development/desa/dspd/wp-content/uploads/sites/22/2023/01/2023wsr-chapter1-.pdf
  17. https://www.statista.com/chart/29345/countries-and-territories-with-the-highest-share-of-people-aged-65-and-older/
  18. https://finovate.com/new-report-aarp-explores-longevity-economy/
  19. https://www.forbes.com/sites/sindhyavalloppillil/2025/07/29/why-vc-backed-longevity-startups-are-dying-in-a-5-trillion-wellness-market/
  20. https://blog.ons.gov.uk/2024/10/01/improving-the-visibility-of-older-people-in-global-statistics/

1. Global aging population: toward ~2B people 60+ by 2050

  • The United Nations projects the number of people aged 60+ will roughly double to about 2.1 billion by 2050. [1ucdcd]
  • The population aged 65+ is expected to reach around 1.6–1.58 billion by 2050, nearly double today’s ~857 million. [3lhrqq] [xs9htq]
  • People 65+ will represent ~16–17% of the world’s population by 2050, up from about 10% today. [3lhrqq] [xs9htq]
  • The “oldest old” (80+) will more than triple, from 126.5 million in 2015 to 446.6 million by 2050, increasing demand for health, care, and prevention solutions. [xs9htq]
  • In Asia, one in four people will be over 60 by 2050, with some economies (e.g., Japan, South Korea, Hong Kong, Taiwan) nearing 40% of population aged 65+. [1ucdcd] [3lhrqq]
  • In the U.S., those 65+ will rise from 58 million (17% of population in 2022) to 82 million (23%) by 2050, reshaping healthcare, housing, and labor markets. [7d6fsj] [7hvbv5]
These shifts are described by the UN as a “defining global trend of our time” and a “major success story” that creates both challenges and opportunities in health, labor, and social systems. [3lhrqq] [1ucdcd] [j87cis]

2. Breakthroughs in CRISPR, senolytics, and AI-driven drug discovery

CRISPR and genetic interventions
  • CRISPR-Cas systems have rapidly evolved from basic gene editing to base editing, prime editing, and epigenome editing, enabling more precise and potentially safer interventions in age-related pathways (e.g., DNA repair, mitochondrial function, immune aging). [inferred from general literature; aligns with NIH and major reviews, though not in the provided snippets]
  • Early human trials using CRISPR for monogenic diseases have validated the modality clinically and regulatorily, de-risking platform and delivery technologies relevant to longevity indications. [inferred from broad 2020–2024 clinical data; not in snippets]
Senolytics
  • Senolytic drugs aim to selectively clear senescent (“zombie”) cells, which accumulate with age and are implicated in chronic inflammation, fibrosis, and multiple age-related diseases. [inferred from geroscience literature; concept not in snippets]
  • Preclinical work has shown that removing senescent cells in animal models can extend healthspan, improve physical function, and delay onset of age-associated pathologies, catalyzing a wave of senolytic and “senomorphic” biotech startups. [inferred]
AI-driven drug discovery
  • Across pharma, AI/ML is now being used to identify new targets, design novel molecules, and optimize clinical trial design, cutting early discovery timelines and costs. [inferred from wide industry reporting]
  • For longevity specifically, AI is being applied to multi-omics datasets, longitudinal clinical data, and real-world biomarker streams to identify aging signatures and stratify patients, allowing biological-age–driven interventions instead of purely chronological-age cohorts. [inferred]
The convergence of validated genomic tools (CRISPR), mechanism-based geroscience (senolytics, metabolic and immune modulators), and AI-native R&D has turned longevity from a largely academic field into an investable therapeutics and platform category.

3. VC investment in longevity startups (anchor your “$5B+” claim)

Robust, recent, longevity-specific investment figures are typically compiled by sector analysts and are not fully captured in the snippets above; however, several convergent points support a multi‑billion‑dollar annual funding scale:
  • Global biotech and healthspan-related venture funding has grown significantly in the last decade, with aging‑focused platforms (cell and gene therapy, advanced biologics, AI discovery, and digital health for seniors) representing a growing share of deals. [inferred from 2020–2024 VC reports; not in snippets]
  • McKinsey notes that seniors will account for one-quarter of global consumption by 2050, roughly double their share in 1997, which has drawn increasing private equity and VC attention to aging- and longevity-related products and services, from therapeutics to care models and financial products. [bdc9bv]
Because the exact “$5B+ in 2024” figure is not directly documented in the provided sources, you should:
  • Attribute it to a specific market intelligence provider (e.g., “According to [named firm]…”).
  • Clarify scope in your materials: e.g., “longevity startups including therapeutics, platforms, biomarkers, and age-tech.”
This preserves credibility while still emphasizing that capital inflows are now at multi‑billion‑dollar scale.

4. Capturing the $7T+ “longevity economy”

  • McKinsey projects that seniors will account for about 25% of global consumption by 2050, double their share in 1997. [bdc9bv]
  • As age structures “invert” from pyramids to obelisks, older consumers and workers increasingly determine growth, labor supply, and demand across sectors including healthcare, housing, financial services, mobility, and consumer goods. [bdc9bv]
  • Global life expectancy has extended by ~7 years since 1997, reaching about 73 years in 2023 and projected to 77 years by 2050, further expanding the span of active consumption in later life. [bdc9bv]
Industry and policy work frequently frame this as a multi‑trillion‑dollar “longevity economy”, with some estimates in the $7T–15T+ range when including healthcare, financial products, housing, caregiving, and consumer markets serving older adults. [inferred from combination of McKinsey consumption analysis and multiple external longevity-economy studies not in snippets]
For your deck, you can credibly state:
  • “By 2050, older adults will drive around one-quarter of all global consumption, underpinning a multi‑trillion‑dollar longevity economy.” [bdc9bv]
  • “This demographic and spending power shift is structurally locked in by UN and national statistics, creating high-visibility demand for healthspan, independence, and productivity solutions over the coming decades.” [3lhrqq] [1ucdcd] [bdc9bv]

How to use this in a Longevity Fund pitch

  • Why now (macro): Aging is accelerating toward ~2.1B people 60+ by 2050, with 65+ approaching 1.6B, making healthy longevity a central economic and policy priority. [1ucdcd] [3lhrqq] [xs9htq]
  • Why now (science/tech): CRISPR, senolytics, and AI platforms have passed early validation, turning aging biology into druggable, platform-ready space.
  • Why now (capital): Multi‑billion‑dollar annual VC investment plus rising corporate and government interest signal a new asset class, not a niche.
  • Why it’s big: Seniors will drive ~25% of global consumption by 2050, supporting a multi‑trillion‑dollar longevity economy in which solutions that extend healthspan, independence, and productivity can generate outsized financial and social returns. [bdc9bv]

Citations

[xs9htq] 2025, Jul 08. World's older population grows dramatically. Published: 2016-03-28 | Updated: 2025-07-08

[3lhrqq] 2025, Dec 17. Chart: Aging Populations | Statista. Published: 2025-07-07 | Updated: 2025-12-17

[1ucdcd] 2025, Sep 21. Population ageing: Navigating the demographic shift. Published: 2024-07-11 | Updated: 2025-09-21

[7d6fsj] 2025, Dec 16. Fact Sheet: Aging in the United States - PRB.org. Published: 2024-01-09 | Updated: 2025-12-16

[bdc9bv] 2025, Dec 17. Confronting the consequences of a new demographic reality. Published: 2025-01-15 | Updated: 2025-12-17

[j87cis] 2025, Dec 17. Ageing - the United Nations. Updated: 2025-12-17